Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $190.7552W HIGH $291.40
Volume
3.11 M
Value Traded
1.04 B
Short % Float
0.88%
Days to Cover
2.7
+0.42%Week
+7.4%1 Month
+8.62%3 Month
+40.27%6 Month
+83.54%5 Year
+482.97%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
505.29 B
EPS (TTM)
3.57
P/E Ratio
80.09
Ent. Value
498.72 B
Total Shares
1.77 B
Float Shares
1.77 B
Insiders
0.10%
Institutions
78.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ABBV Catalyst Timeline
Dated clinical, regulatory and corporate events for AbbVie Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for AbbVie Inc.
2804Total events
30Upcoming
1184Tier-1 (high impact)
2013 to 2030Coverage
Upcoming catalysts 2
Event history 50
●BLA SubmissionEtentamigFiledRegulatory Filing
AbbVie submits BLA to FDA for etentamig in relapsed/refractory multiple myeloma
relapsed or refractory multiple myelomasource ↗
▲Safety Label ChangeSKYRIZIApprovedPost-Market
FDA approves update to SKYRIZI US prescribing information TB warning/precautions language across all indications
all approved indicationssource ↗
▲FDA ApprovalSKYRIZIApprovedFDA Decision
FDA approves subcutaneous induction regimen for SKYRIZI in Crohn's disease
moderately to severely active Crohn's diseasesource ↗
▲Topline ReadoutLutikizumabClinical Data
Positive topline results from Phase 3 INTREPID in moderate to severe HS
hidradenitis suppurativasource ↗
▲Secondary Endpoint DataLutikizumabClinical Data
Lutikizumab met 8 ranked secondary endpoints including pain and flares
hidradenitis suppurativasource ↗
●Safety Data UpdateLutikizumabClinical Data
Lutikizumab generally well tolerated with no new safety concerns
hidradenitis suppurativasource ↗
▲Primary Endpoint MetLutikizumabClinical Data
Lutikizumab met primary endpoint HiSCR75 at Week 16 vs placebo
hidradenitis suppurativasource ↗
▲Additional DataABBV-466Clinical Data
ABBV-466 Week 24 endoscopic remission (40.5%) and tissue remodeling gene expression data
Moderate to severe Crohn's diseasesource ↗
▲Primary Endpoint MetABBV-466Clinical Data
ABBV-466 met primary endpoint of endoscopic remission at Week 12 in Phase 2a TARGET-CD
Moderate to severe Crohn's diseasesource ↗
▲Late-BreakerABBV-466Presentation
TARGET-CD primary results presented as late-breaker at 2026 UEGW Congress
Moderate to severe Crohn's diseasesource ↗
●Safety Data UpdateABBV-466Clinical Data
ABBV-466 SAE rate 10.4%, comparable to monotherapies
Moderate to severe Crohn's diseasesource ↗
▲Full ResultsSKYRIZIApprovedClinical Data
AFFIRM Phase 3 full endoscopic remission and ulcer-free endoscopy results presented at ACG 2026
moderately to severely active Crohn's diseasesource ↗
▲Oral PresentationSKYRIZIApprovedPresentation
AFFIRM data presented at ACG 2026 Annual Scientific Meeting
moderately to severely active Crohn's diseasesource ↗
▲Additional DataSKYRIZIApprovedClinical Data
New AFFIRM Phase 3 endoscopic remission and ulcer-free endoscopy data presented at ACG 2026
moderately to severely active Crohn's diseasesource ↗
▲Breakthrough Therapy Designationtelisotuzumab adizutecanDesignation
FDA grants Breakthrough Therapy Designation to Temab-A plus bevacizumab in refractory metastatic CRC
refractory, metastatic colorectal cancer (CRC)source ↗
▲Topline ReadoutEpcoritamabApprovedClinical Data
Positive topline results from Phase 3 EPCORE DLBCL-2 of epcoritamab plus R-CHOP in newly diagnosed DLBCL
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Secondary Endpoint DataEpcoritamabApprovedClinical Data
Key secondary endpoint of PFS in total participants (IPI 2-5) met with 51% risk reduction
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Safety Data UpdateEpcoritamabApprovedClinical Data
Epcoritamab plus R-CHOP safety profile generally well tolerated in EPCORE DLBCL-2
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲DSMB ReviewEpcoritamabApprovedTrial
IDMC recommended unblinding EPCORE DLBCL-2 based on significant benefit
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Primary Endpoint MetEpcoritamabApprovedClinical Data
EPCORE DLBCL-2 met primary endpoint of PFS in IPI 3-5 patients
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
▲Interim AnalysisEpcoritamabApprovedTrial
First planned efficacy interim analysis of EPCORE DLBCL-2
newly diagnosed diffuse large B-cell lymphoma (DLBCL)source ↗
◆Oral PresentationUpadacitinibApprovedPresentation
Oral presentation of pooled patient-reported outcomes with upadacitinib in nonsegmental vitiligo through Week 48 from two Phase 3 trials
non-segmental vitiligosource ↗
◆Late-BreakerUpadacitinibApprovedPresentation
Late-breaking presentation of upadacitinib efficacy and safety in adolescents and adults with non-segmental vitiligo at Week 76 and in combination with NB-UVB therapy
non-segmental vitiligosource ↗
◆Oral PresentationUpadacitinibApprovedPresentation
Oral presentation on impact of upadacitinib on clinician- and patient-reported outcomes assessing visible hair loss at key sites in severe alopecia areata
severe alopecia areatasource ↗
●Oral PresentationUpadacitinibApprovedPresentation
Late-breaking oral presentation of long-term Viti-Up data at 2026 EADV Congress
non-segmental vitiligosource ↗
●Safety Data UpdateUpadacitinibApprovedClinical Data
Safety results through week 76 consistent with known upadacitinib profile
non-segmental vitiligosource ↗
▲Long Term DataUpadacitinibApprovedClinical Data
Continued F-VASI 75 and T-VASI 50 repigmentation through week 76 in OLE
non-segmental vitiligosource ↗
▲Additional DataUpadacitinibApprovedClinical Data
Week 28 results of RINVOQ plus NB-UVB phototherapy substudy
non-segmental vitiligosource ↗
▲Late-BreakerUpadacitinibApprovedPresentation
Late-breaking results from Phase 3 Viti-Up-1 and Viti-Up-2 presented at 2026 EADV Congress
non-segmental vitiligosource ↗
▲Primary Endpoint MetzumilokibartClinical Data
Zumilokibart met primary endpoint (EASI-75 at Week 16) in Phase 2 APEX Part B
moderate to severe atopic dermatitissource ↗
◆Late-BreakerzumilokibartPresentation
Late-breaking presentation of primary 16-week results from Phase 2 APEX Part B dose-regimen-finding study of zumilokibart in moderate to severe AD
moderate to severe atopic dermatitissource ↗
▲Oral PresentationABBV-295Presentation
Detailed Phase 1 MAD results for ABBV-295 presented at EASD 2026
obesitysource ↗
◆Poster PresentationzumilokibartPresentation
Digital e-poster on efficacy of zumilokibart in patients with atopic dermatitis and evidence of type 2 inflammatory comorbidities from Phase 2 APEX Part A study
atopic dermatitissource ↗
◆Poster PresentationLutikizumabPresentation
Digital e-poster on patient-reported quality of life and disease burden in biologic-naive adults with moderate-to-severe HS treated with lutikizumab from Phase 2 study
hidradenitis suppurativasource ↗
◆Poster PresentationUpadacitinibApprovedPresentation
Digital e-poster on efficacy of upadacitinib in patients with itch-dominant atopic dermatitis from Phase 3 Measure Up 1 and 2 trials
atopic dermatitissource ↗
◆Late-BreakerLutikizumabPresentation
Late-breaking presentation showing lutikizumab targets neutrophilic inflammation and fibroblast activation in HS
hidradenitis suppurativasource ↗
◆Poster PresentationRisankizumabApprovedPresentation
Digital e-poster on efficacy of risankizumab in prevention of radiographic progression in PsA patients at low and high risk of joint erosive disease: 5-year data from Phase 3 KEEPsAKE 1 trial
psoriatic arthritissource ↗
▲Secondary Endpoint DatazumilokibartClinical Data
Mid- and high-dose regimens showed significant improvements in EASI 90/100 and I-NRS4 vs placebo
moderate to severe atopic dermatitissource ↗
●Safety Data UpdatezumilokibartClinical Data
Safety data reported for zumilokibart through Week 16
moderate to severe atopic dermatitissource ↗
▲Partnership / LicenseCorporate
AbbVie enters AI collaboration with Valkai across clinical development
▲FDA ApprovalJUVMOApprovedFDA Decision
U.S. FDA approves JUVMO (tavapadon) for adults with Parkinson's disease
Parkinson's diseasesource ↗
▲Manufacturing MilestoneCMC / Inspection
Construction phase completed for AbbVie Foundation Cancer Pavilion
▲EU ApprovalUpadacitinibApprovedEx-US Regulatory
European Commission approves RINVOQ for active polyarticular juvenile idiopathic arthritis in patients 2 years and older
active polyarticular juvenile idiopathic arthritis (pJIA)source ↗
▲FDA ApprovalUpadacitinibApprovedFDA Decision
New oral solution of RINVOQ approved for use in patients with pJIA
active polyarticular juvenile idiopathic arthritis (pJIA)source ↗
▲Partnership / LicenseCorporate
AbbVie and Iambic announce multi-year collaboration for AI-driven small molecule discovery
▲RWE DataCariprazineApprovedClinical Data
ProACt interim real-world data of adjunctive VRAYLAR in MDD presented at Psych Congress 2026
major depressive disorder (MDD)source ↗
●Additional DataCariprazineApprovedClinical Data
Indirect comparative analysis of cariprazine and lumateperone as adjunctive MDD treatment presented
major depressive disorder (MDD)source ↗
▲Long Term DataCariprazineApprovedClinical Data
Final long-term pediatric safety and tolerability results for VRAYLAR presented
bipolar I disorder, schizophrenia or autism spectrum disorder (pediatric)source ↗
●Additional DataCariprazineApprovedClinical Data
MDD patient survey on augmenting vs switching antidepressants presented at Psych Congress 2026
major depressive disorder (MDD)source ↗
●RWE DataClinical Data
MDD patient survey on augmenting vs switching antidepressants presented
major depressive disorder (MDD)source ↗
Past FDA Catalysts and PDUFA Decisions
How ABBV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-23 | ABBV-969 | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
95
Drugs Scored
rNPV / MCap
Top Drug
Top 2%
Large Pharma(rank 14 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| SKYRIZI | |||
| RINVOQ | |||
| Botox Therapeutic | |||
| Vraylar | |||
| HUMIRA | |||
| VENCLEXTA | |||
| Botox Cosmetic | |||
| Imbruvica | |||
| Creon | |||
| Ubrelvy | |||
| MAVYRET | |||
| Qulipta |
Top 12 of 17 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV-1480 Small moleculeNCT07756645 | Non-Small Cell Lung Cancer | Phase 3 | RECRUITING | 940 | Dec 1, 2029 | ||||||
| ABBV-706 Small moleculeNCT07155174 | Small Cell Lung Cancer | Phase 3 | RECRUITING | 711 | Sep 1, 2031 | ||||||
| ABBV-706 Small moleculeNCT05599984 | Advanced Solid Tumors | Phase 1 | ACTIVE NOT_RECRUITING | 288 | Nov 1, 2027 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT06464692 | Colorectal Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,161 | Dec 1, 2027 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT07821684 | Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | NOT YET_RECRUITING | 1,514 | Apr 1, 2031 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT06614192 | Metastatic Colorectal Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 464 | Aug 1, 2027 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT07196644 | Solid Tumors Harboring MET Amplification | Phase 2 | RECRUITING | 100 | Dec 1, 2030 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT07155187 | Non-Small Cell Lung Cancer | Phase 2 | RECRUITING | 490 | Sep 1, 2030 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT06628310 | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma | Phase 2 | ACTIVE NOT_RECRUITING | 185 | Oct 1, 2030 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT07769502 | Pancreatobiliary Cancers | Phase 2 | RECRUITING | 168 | Sep 1, 2028 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT07744126 | Head and Neck Squamous Cell Carcinoma | Phase 2 | RECRUITING | 150 | Oct 1, 2029 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT07490301 | Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | RECRUITING | 900 | Jun 1, 2031 | ||||||
| ABBV-400 Small moleculeNCT06107413 | Unresectable Metastatic Colorectal Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 280 | Dec 1, 2026 | ||||||
| ABBV-400 Small moleculeNCT05029882 | Non-Small Cell Lung Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 520 | Nov 1, 2027 | ||||||
| Telisotuzumab Adizutecan Monoclonal antibodyNCT06772623 | Non Small Cell Lung Carcinoma | Phase 1 | RECRUITING | 252 | Nov 1, 2027 | ||||||
| ABBV-400 Small moleculeNCT06084481 | Hepatocellular Carcinoma | Phase 1 | RECRUITING | 325 | Sep 1, 2027 | ||||||
| Etentamig Small moleculeNCT07793422 | Amyloid Light Chain (AL) Amyloidosis | Phase 3 | NOT YET_RECRUITING | 370 | Dec 1, 2034 | ||||||
| Etentamig Small moleculeNCT07728188 | Relapsed or Refractory Multiple Myeloma | Phase 3 | NOT YET_RECRUITING | 520 | Feb 1, 2033 | ||||||
| Etentamig Small moleculeNCT06223516 | Multiple Myeloma | Phase 3 | ACTIVE NOT_RECRUITING | 2,108 | Dec 1, 2027 | ||||||
| ABBV-383 Small moleculeNCT06158854 | Immunoglobulin Light Chain (AL) Amyloidosis | Phase 1 | RECRUITING | 76 | Aug 1, 2031 | ||||||
| TNB-383B Small moleculeNCT03933735 | Multiple Myeloma | Phase 1 | ACTIVE NOT_RECRUITING | 220 | May 1, 2026 | ||||||
| Etentamig Small moleculeNCT05286229 | Relapsed/Refractory Multiple Myeloma | Phase 1 | ACTIVE NOT_RECRUITING | 291 | Mar 1, 2026 | ||||||
| Surabgene Lomparvovec Gene therapyNCT04514653 | Neovascular Age-related Macular Degeneration | Phase 3 | ACTIVE NOT_RECRUITING | 707 | Feb 1, 2027 | ||||||
| Surabgene Lomparvovec Gene therapyNCT04704921 | AMD | Phase 3 | ACTIVE NOT_RECRUITING | 1,406 | Nov 1, 2027 | ||||||
| Surabgene Lomparvovec Gene therapyNCT04567550 | Diabetic Retinopathy | Phase 2 | ACTIVE NOT_RECRUITING | 715 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ABBV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| lutikizumab | hidradenitis suppurativa | Phase 3 | 2026-10-22 | primary endpoint: 31.4% versus 23.4%; p≤0.001; NRS3: 26.2% versus 15.0%; p<0.0001; NRS30: 36.0% versus 22.8%; p<0.0001; HS flares: 18.4% versus 28.1%; p<0.0001Read More | AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis SuppurativaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Donoghoe NicholasOfficer (EVP, CHIEF BUS/STRAT OFFICER) | Option | 32,710 107,140 held | $79.02 | 08/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ABBV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 1.7 % (-22.7 %) | 16.31 M | 75.00 K | 64% ( 29.27 K) |
ABBV Institutional Ownership Trends
ABBV Short Interest
Shares sold short, counted twice a month.
0.88%
Short % of Float
of tradable shares sold short
15.6M
Shares Sold Short
-4.3% vs prior count
2.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
5.7M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ABBV ranks across every disease it competes in
Competitive Position is a premium feature
See how ABBV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialABBV News
ABBV▼ -0.1%today
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
AbbVie submitted a Biologics License Application for etentamig, a bispecific antibody for relapsed/refractory multiple myeloma. The Phase 3 CERVINO study demonstrated significant improvements in overall response rate and progression-free survival. The drug aims to provide a patient-centered treatment option with a manageable safety profile and monthly dosing.
Read more →ABBVU.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
AbbVie announced FDA approval for a subcutaneous induction regimen of SKYRIZI for adults with moderately to severely active Crohn's disease. The approval is based on the Phase 3 AFFIRM study, showing superior clinical remission and endoscopic response at week 12 compared to placebo. Patients can now initiate treatment at home using an on-body injector device.
Read more →ABBVAbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
AbbVie announced positive topline results from the Phase 3 INTREPID study, where lutikizumab significantly improved signs and symptoms in patients with moderate to severe hidradenitis suppurativa. The study met its primary endpoint of HiSCR75 at Week 16 and demonstrated notable improvements in pain and flare occurrences. Lutikizumab was well tolerated with no new safety concerns.
Read more →ABBVAbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
AbbVie announced positive results from its Phase 2a study of ABBV-466, a dual-targeting therapy for moderate to severe Crohn's disease. The therapy achieved higher endoscopic remission rates at Week 12 compared to existing monotherapies. Gene expression analysis indicated significant intestinal repair and metabolic changes. These findings will be presented at the 2026 UEGW Congress.
Read more →ABBVAbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
AbbVie will showcase new data at the 2026 ESMO Congress, focusing on its solid tumor portfolio. The presentations will cover seven assets across various cancers, highlighting advancements in treatment approaches and promising clinical outcomes. Notably, Temab-A has shown encouraging results in colorectal and lung cancers, reinforcing AbbVie's commitment to oncology innovation.
Read more →ABBVAbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
AbbVie presented new Phase 3 AFFIRM study data showing that subcutaneous SKYRIZI (risankizumab-rzaa) significantly improves endoscopic remission and ulcer-free endoscopy rates in patients with moderately to severely active Crohn's disease. The findings indicate that 35.8% of patients achieved endoscopic remission after treatment, with even higher rates in therapy-naïve patients. This data supports AbbVie's application to the FDA for a new induction dosing regimen.
Read more →ABBVAbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
AbbVie announced that its investigational drug, telisotuzumab adizutecan (Temab-A), has received two Breakthrough Therapy Designations from the FDA for colorectal cancer and non-small cell lung cancer. These designations underscore the drug's potential as a treatment for patients with advanced solid tumors. Temab-A is being studied both as a monotherapy and in combination with other therapies.
Read more →ABBVAbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, which evaluated the bispecific antibody epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The trial demonstrated a 51% reduction in the risk of disease progression or death, indicating a significant improvement in progression-free survival. The companies plan to engage global regulatory authorities based on these results.
Read more →ABBVGenmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, demonstrating that the bispecific antibody epcoritamab in combination with R-CHOP significantly improves progression-free survival in newly diagnosed DLBCL patients. The study showed a 51% reduction in the risk of disease progression or death. The companies plan to engage global regulatory authorities based on these findings.
Read more →ABBVAbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
AbbVie presented long-term data on RINVOQ (upadacitinib) at the 2026 EADV Congress, demonstrating sustained facial and total body repigmentation in non-segmental vitiligo patients through week 76. The Phase 3 Viti-Up studies indicated improved outcomes when RINVOQ was combined with NB-UVB phototherapy. Safety results remained consistent with previous findings, with no new safety concerns reported.
Read more →ABBVAbbVie to Host Third-Quarter 2026 Earnings Conference Call
AbbVie will announce its third-quarter 2026 financial results on October 30, 2026, before market opening. A live webcast of the earnings conference call will take place at 8 a.m. Central time, accessible via AbbVie's Investor Relations website. An archived version will be available later that day.
Read more →ABBVAbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
AbbVie presented detailed Phase 1 data for ABBV-295, a long-acting amylin analog, at the EASD 2026 Annual Meeting. The study showed favorable pharmacokinetics, including a half-life of approximately 11-12 days, and demonstrated meaningful weight loss across multiple dosing regimens. The results support advancing ABBV-295 into Phase 2 development for chronic weight management.
Read more →ABBVAbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
AbbVie announced positive results from the Phase 2 APEX Part B study of zumilokibart for moderate to severe atopic dermatitis. All dose regimens met the primary endpoint, with significant improvements in skin lesions and itch. The mid-dose regimen has been selected for Phase 3 development, supporting its potential as a long-term treatment option.
Read more →ABBVAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie showcased its leadership in dermatology research at the 2026 EADV Congress, presenting 60 abstracts across various immune-mediated skin diseases. Key findings included new data on risankizumab and upadacitinib, which support their efficacy and safety. Investigational therapies lutikizumab and zumilokibart were also highlighted, indicating AbbVie's commitment to advancing treatment options for patients.
Read more →ABBVAbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
AbbVie has partnered with Valkai to enhance its artificial intelligence capabilities in clinical development. This collaboration aims to streamline research processes, generate insights more rapidly, and ultimately improve patient outcomes. The initiative reflects AbbVie's commitment to integrating AI throughout its drug development journey, leveraging advanced technology alongside human expertise.
Read more →ABBVGinkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Ginkgo Datapoints and Apheris have announced the inclusion of AbbVie, argenx, Lundbeck, and Takeda as founding members of the Antibody Developability Consortium. This collaboration aims to enhance the development processes for antibodies, leveraging the expertise of these leading biopharma companies. The consortium is expected to drive innovation in the field.
Read more →ABBVU.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
The U.S. FDA has approved AbbVie's JUVMO™ (tavapadon) as the first selective D1/D5 receptor agonist for adults with Parkinson's disease. This novel treatment offers a new approach to managing motor symptoms and has shown significant efficacy in clinical trials, reducing the need for increased doses of oral levodopa. JUVMO is expected to be available to patients in October 2026.
Read more →ABBVUChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality
The University of Chicago Medicine has completed the construction of the AbbVie Foundation Cancer Pavilion, a 575,000-square-foot facility dedicated to cancer care. Set to open in April 2027, this project aims to enhance access to advanced cancer treatments and improve health outcomes in underserved communities. The pavilion will serve approximately 200,000 outpatient visits and 5,000 inpatient admissions annually.
Read more →ABBVEPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
AbbVie announced that Health Canada has approved EPKINLY® for adults with relapsed or refractory follicular lymphoma. This treatment, in combination with lenalidomide and rituximab, has shown a 79% reduction in the risk of disease progression or death in clinical trials. The approval highlights the need for effective therapies for a disease that is often incurable.
Read more →ABBVAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
AbbVie has received European Commission approval for RINVOQ (upadacitinib) to treat active polyarticular juvenile idiopathic arthritis (pJIA) in children aged two and older who have not responded adequately to DMARDs. The approval is based on the SELECT-YOUTH Phase 1 study, demonstrating significant efficacy and safety. RINVOQ is now approved for 11 indications in the EU, expanding treatment options for pediatric patients.
Read more →About AbbVie Inc.
Headquarters1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064
Founded2011
BIOPHARMAWATCH ELITE PLUS
Trade the next ABBV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime